Navigation Links
Intra-Cellular Therapies Cleared for Quotation on OTCQB
Date:12/19/2013

molecule in the ITI/Takeda collaboration, ITI-214.  The Company has additional programs in the areas of Parkinson's disease, Alzheimer's disease, depression and cardiovascular disease.

Forward-looking Statements

This news release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, the expected timing of the commencement of trading on the OTCQB of our common stock, the results of our Phase 2 clinical trial of ITI-007 in patients with acutely exacerbated schizophrenia, and our research and development efforts and plans under the caption "About Intra-Cellular Therapies." All such forward-looking statements are based on management's present expectations and are subject to certain factors, risks and uncertainties that may cause actual results, outcome of events, timing and performance to differ materially from those expressed or implied by such statements. These risks and uncertainties include, but are not limited to the following: our current and planned clinical trials for ITI-007 and our other product candidates may not be successful or may take longer and be more costly than anticipated;  product candidates that appeared promising in early research and clinical trials may not demonstrate safety and/or efficacy in larger-scale or later clinical trials; our reliance on collaborative partners and other third-parties for further clinical trials, development and commercialization of our product candidates; the costs associated with our research, development and other activities may exceed those that we estimate; the conduct and results of preclinical and clinical studies of our product candidates may pose ch
'/>"/>

SOURCE Intra-Cellular Therapies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Intra-Cellular Therapies Announces Closing of $60 Million Private Placement and Completion of Reverse Merger
2. Intra-Cellular Therapies Announces Completion of Phase I Single Rising Dose Trial of First-in-Class Selective Phosphodiesterase 1 (PDE1) Inhibitor and Reports Top-line Safety and Pharmacokinetic Findings
3. Immunotherapies Will Continue to Dominate the Malignant Melanoma Drug Market with Sales of Immune Checkpoint Inhibitors Accounting for Majority of Sales in this Drug Class in 2022
4. The Leukemia & Lymphoma Societys (LLS) Greater Bay Area Chapter to Host the 2014 Emerging Therapies & Survivorship Conference
5. Sangamo BioSciences Presents Data From Non-Human Primates Providing Proof Of Concept For Disruptive And Broadly Leverageable Platform For Protein Replacement Therapies
6. Improved Efficacy, Limited Toxicity of Targeted Therapies Brighten the Future of Treatment for Chronic Lymphocytic Leukemia
7. Innovative Compounds, Combination Therapies Improve Care of Patients with Wide Range of Blood Disorders
8. Study Confirms Efficacy of Innovative Therapies Quantum Negative Pressure Wound Therapy (NPWT) in Enhancing Wound Healing
9. Contrasting Reimbursement Environments Result in Different Prescribing Patterns for Premium-Priced Therapies in China and South Korea
10. U.S. Claims Data Show Declining Use of Platform Injectables as Oral Multiple Sclerosis Therapies Gain Traction
11. In the Psoriasis Drug Market, Continued Uptake of Janssens Stelara and the Launch of Emerging Systemic Therapies Will Drive Sales Growth to Nearly $9.2 Billion in 2022
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... LONDON , August 28, 2015 ... approach seamlessly connects people, technologies and care protoc ... improving outcomes and the cost of healthcare delivery   ... PHIA) today announced its presence at  ESC Congress 2015 , where ... Model A.I. , EchoNavigator and IntelliSpace Cardiovascular, that connect people ...
(Date:8/27/2015)... Va. , Aug. 27, 2015  The ... the Food and Drug Administration,s (FDA,s) draft guidance ... reference products and biosimilars, to bear a nonproprietary ... AMCP has been seeking a decision from the ... 18 diverse health care stakeholders urging the agency ...
(Date:8/27/2015)... DURECT Corporation (Nasdaq: DRRX ) announced ... upcoming healthcare conferences.  , James ... the Rodman & Renshaw Investment Conference on Thursday, September ... being held at the St. Regis Hotel in ... webcast of the presentation will be available by accessing ...
Breaking Medicine Technology:Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 2Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 3Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 4AMCP Is Disappointed in FDA's Draft Guidance and Proposed Rule Calling for Suffix on Nonproprietary Names of Biological Products 2DURECT to Participate in Upcoming Healthcare Conferences 2
... FOLD ) today announced that John F. Crowley ... Chairman in order to devote more time to interests related ... role as Executive Chairman, Mr. Crowley will continue to perform ... will advise the current Amicus management team on corporate strategy ...
... The board of directors of Eli Lilly and Company (NYSE: ... second quarter of 2011 of $0.49 a share on outstanding ... 10, 2011 to shareholders of record at the close of ... innovation-driven corporation, is developing a growing portfolio of pharmaceutical products ...
Cached Medicine Technology:Amicus Therapeutics Announces Transition of John F. Crowley from Chairman and Chief Executive Officer to Executive Chairman 2
(Date:8/28/2015)... , ... August 28, 2015 , ... ... grams of high grade protein with zero fat, carbs, sugar, gluten, lactose or ... named a finalist for the 2015 SupplySide CPG Editor’s Choice Awards. , Five ...
(Date:8/28/2015)... ... August 28, 2015 , ... Medical Solutions, one of the nation’s largest ... Work in Healthcare by Modern Healthcare and will be honored at an awards ... eighth year, the Best Places to Work in Healthcare program recognizes outstanding employers in ...
(Date:8/28/2015)... ... 2015 , ... SmartPractice Calendars afford dental offices ... contact information and logos, Calendars stand alone as functional brand-building giveaways ... mailings, thank you and welcome communications, and to complement statements and invoices. 2016 ...
(Date:8/28/2015)... ... August 28, 2015 , ... SharkNinja, an innovative leader in ... Emmy-nominated actress, Sofia Vergara, and unveil the Ninja® brand’s new coffee machine, ... delivers a variety of sizes and styles while achieving the perfect brew richness ...
(Date:8/28/2015)... Washington, DC (PRWEB) , ... ... ... Atlantic Information Services, Inc.’s (AIS) Medicare-Medicaid Dual Eligibles Database have added comprehensive ... newest CMS-backed alignment demonstration approved for a December 2015 launch; and Idaho’s ...
Breaking Medicine News(10 mins):Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 2Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 3Health News:Medical Solutions Recognized as One of 2015 Best Places to Work in Healthcare 2Health News:Medical Solutions Recognized as One of 2015 Best Places to Work in Healthcare 3Health News:SmartPractice® Introduces 2016 Calendars for Dental Practice Giveaways 2Health News:Sofia Vergara Partners With SharkNinja® To Launch The Ninja Coffee Bar™ 2Health News:Sofia Vergara Partners With SharkNinja® To Launch The Ninja Coffee Bar™ 3Health News:AIS Duals Database: August Update Finds Two New Duals Programs in Rhode Island and Idaho 2
... microscope, scientists have tried to visualize smaller and smaller structures ... bacteria and viruses. Now, researchers at the National Institute ... the National Institutes of Health, have developed a new way ... before. Their findings are reported in the Jan. 13 ...
... (HealthDay News) -- The chemotherapy used to treat a form ... the return of the disease within years, a new study ... who thought chemotherapy drugs could disrupt DNA through mutations and ... medications. "Chemotherapy drugs are absolutely necessary to get ...
... Jefferson,s Kimmel Cancer Center has started a ... cancer chemotherapy drug to extend survival, Cabazitaxel, in ... approach could improve disease control and eventually survival ... single-center, open-label, non-randomized Phase I study ...
... Using two cell surface markers found to be ... researchers at Moffitt Cancer Center, working with colleagues ... imaging probes that can non-invasively detect breast cancer ... breast cancer patients invasive and unreliable sentinel lymph ...
... women are scarce leads men to become impulsive, save less, ... of Minnesota,s Carlson School of Management. "What we see ... become more competitive. They compete more for access to mates," ... Carlson School and lead author of the study. "How do ...
... language are quicker at recognizing and interpreting body language than ... Davis and UC Irvine. The work suggests that deaf ... visual traits in the actions of others, an ability that ... screening. "There are a lot of anecdotes about deaf ...
Cached Medicine News:Health News:NIH scientists identify novel approach to view inner workings of viruses 2Health News:DNA Damage From Chemo May Help Spur Leukemia's Return 2Health News:Cabazitaxel with radiation and hormone therapy may improve prostate cancer survival 2Health News:Researchers find new, noninvasive way to identify lymph node metastasis 2Health News:A scarcity of women leads men to spend more, save less 2Health News:A scarcity of women leads men to spend more, save less 3Health News:Deaf sign language users pick up faster on body language 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: